A company hopelessly lost with little to no strategic vision. Rose was given a poor poker hand and was unable to draw any new cards. She will go down as another leader from Pharma who could not cut it in the small company world.
C suite is a revolving door. Full turnover on all C positions x3 or so for the past three years. The board is now trying a bunch of CareFX retreads. Revenue stagnant, so cost cuts will make the numbers.